In 2013, Norway established a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method”.
In this framework, all innovations should undergo HTA before being funded. If the method concerns only one or two hospitals, the assessment shall be initiated by clinicians and ran at the hospital level. The final report is disseminated via a mini-HTA database. If the method is of national concern, it undergoes Single Technology Appraisal at the national level, followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum).
In August 2021, the mini-HTA evaluation of the robot-assisted percutaneous coronary intervention was released. Initially, the assessment was launched within the framework for the managed introduction of innovations “New Methods” at the University Hospital of North Norway.
The method was described as safe and effective; however, the innovation project will evaluate its benefits and future potential after the first phase. After the introduction into the clinical practice, the method should be followed up for two years with a sufficient number of procedures to understand the real benefit. All procedures are to be registered in the Norwegian Registry for Invasive Cardiology.
The full details in Norwegian can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.